Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study of the Efficacy and Safety of Oral AMT-101 in Adults with Active Rheumatoid Arthritis who have demonstrated an inadequate Response to anti-TNF therapy

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study of the Efficacy and Safety of Oral AMT-101 in Adults with Active Rheumatoid Arthritis who have demonstrated an inadequate Response to anti-TNF therapy

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AMT 101 (Primary) ; Tumour necrosis factor alpha inhibitors
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms CASTRO
  • Sponsors Applied Molecular Transport

    • Most Recent Events

    • 02 May 2023 Status changed from recruiting to discontinued.
    • 27 Mar 2023 According to an Applied Molecular Transport media release, after an extensive assessment of our clinical programs and the current business environment, the company have made the difficult decision to pause research and development as we close out existing programs and explore ending this trial at its current enrollment.
    • 27 Mar 2023 According to an Applied Molecular Transport media release, the company's board of directors approved a workforce reduction of approximately 57% of its employee base and the engagement of MTS Health Partners, L.P. as advisors in a process to explore strategic alternatives for the company.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top